The present study retrospectively analyzed the difference in conventional laboratory blood metrics among CRC, CRA and CRP. It was found that 49 of 76 (64.5%) indicators significantly differed between CRC and CRA&P. Furthermore, 54 indicators were significant for discriminating CRC from CRA&P, with AUCs ranging within 0.537–0.815. In addition, 19 indicators had AUCs > 0.7, three indicators had AUCs > 0.8, and five indicators had AUCs greater than that for CEA. Moreover, 15 of 16 indicators had overall sensitivities comparable with CEA at a specificity of 90% for the diagnosis of CRC (35.7–55.4% vs. 47.7%, all P > 0.05). For differentiating early CRC (TNM stage I + II) from CRA&P, the sensitivities of 15 indicators ranged within 30.4%-55.5% at a specificity of 90%, but there were no significant differences from CRCs at stage III + IV. Eight clinical indicators had AUCs greater than that for CEA in differentiating early CRC (stage I + II) from CRA&P (0.757–0.847 vs. 0.742). In addition, the 15 indicators were not or weakly correlated with CEA (absolute r = 0.058–0.333). These results indicate that many conventional laboratory indicators are valuable for diagnosing CRC, including early CRC, and are comparable to CEA.
In the present study, 16 of 23 indicators of blood cell analysis in CRC were significantly different from CRA&P, which is consistent with the meta-analysis of the full blood count test for CRC detection [18]. All eight RBC-related indicators had significant differences between CRC and CRA&P, and the hemoglobin-related indicators (HCT, MCH and MCHC) had larger AUCs for CRC diagnosis compared to the volume-related indicators (MCV, RDW-CV and RDW-SD). HGB exhibited the highest value for the diagnosis of CRC, and there were no differences between early-stage and late-stage CRCs. Anemia is a frequent sign in CRC patients due to tumor hemorrhage, which induces iron deficiency, especially with tumors in the proximal colon and at the advanced stage [19]. The iron deficiency-related indicator, ferritin, also significantly decreased in CRC and this is consistent to a previous report [20], which further confirms the above anemia-related results. In addition, these present results exhibited that the levels of hemoglobin-related indicators (HCT, MCH, MCHC) were significantly reduced in the CRC of stage I compared with the CRA&P (data not shown), but there were no significant differences among the various stages (Table 4). These are similar to the results of a recent study, in which the levels of HGB, MCV and serum ferritin (SF) decreased shortly before the CRC diagnosis [21].
Apart from the RBC-related indicators, most of the WBC- and PLT-related indicators were valuable for the CRC diagnosis, but these were not as good as the RBC-related indicators, and only two indicators (NEUT% and LYMP%) had an AUC of > 0.7. WBC-related indicators indicate the inflammatory condition of body. Inflammation has been well-known to be closely associated with the onset and progression of cancer, including CRC. The inflammatory cells and cytokines in tumors have been considered to more likely contribute to tumor growth, progression, and immunosuppression, when compared to mounting an effective host anti-tumor response [22]. In addition to the lower circulation lymphocyte number and percentage, and higher circulation neutrophil number and percentage in CRC, when compared to CRA&P, significantly higher levels of C-reactive protein (C-RP) and fibrinogen (FIB) were also found in the present study, and both of these presented AUCs greater than 0.7 for the diagnosis of CRC. These results are consistent with the reports, in which low tumor CD4 + T-lymphocyte infiltration is associated with elevated C-RP concentration and poor cancer-specific survival in CRC patients [23] and FIB is epidemiologically and mechanistically linked with diseases with an inflammatory component [24].
Furthermore, 10 of 20 liver function indicators with AUCs > 0.6 for discriminating CRC from CRA&P, PALB, RBP and CHE presented the greatest AUCs (0.807–0.819) in all indicators, with the diagnostic performance at the “good” level. This was superior to CEA, and but was not different between early- and late-stage CRC patients. Although it has been early found that blood levels of PALB and RBP are correlated to the nutrition and prognosis of CRC [25], the diagnostic value of PALB has just been recently reported. Sun et al. [26] used the ratio of circulating FIB to PALB levels to diagnose CRC, and obtained an AUC of 0.845. In the present study, PALB and RBP had a similar diagnostic performance for CRC, but PALB had a higher sensitivity than ALB. This may be because PALB has a much shorter half-life than ALB (2 vs. 20 days), as well as a smaller body pool and a more rapid synthesis rate. Therefore, PALB was considered the most sensitive and stable indicator, when compared to ALB, in terms of nutritional evaluation [27, 28]. Malnutrition in CRC is more frequent, when compared to other common cancers [29], and early-stage CRC can present apparent sarcopenia, and correlate to survival [30]. These features make PALB valuable in the early diagnosis of CRC. RBP strongly interacts with PALB, and circulates in plasma in a 1:1 molar RBP-PALB complex [31]. Thus, a similar diagnostic performance was observed in the present study.
Among all indicators, serum cholinesterase (CHE) exhibited the highest AUC for the diagnosis of CRC, including early CRC. The reduced serum CHE activity has been early reported in cancer, when compared to normal control [32], and in CRC, when compared to non-cancer patients [33]. Furthermore, this has been considered to be a prognostic factor for CRC patients [34], but this has not been evaluated for the diagnosis of CRC. The diagnosis value of CHE for CRC is probably correlated to its association with inflammation and malnutrition. It was found that serum CHE activity inversely correlates with subclinical inflammation [35] and severe systemic inflammation [36]. In the present study, negative correlations were observed between serum CHE activity and C-reactive protein (r = -0.278) and NEUT% (r = -0.275). CHE activity reduction in inflammation is correlated to the cholinergic anti-inflammatory pathway, in which acetylcholine, the substrate of CHE, plays an anti-inflammatory function and regulates the CHE activity in a negative-feedback manner [36]. Low CHE activity is also a serum marker of nutritional status in patients with CRC [37], and an increase of CHE activity was found after nutritional support therapy [38]. In addition, it was found that CHE is downregulated in CRC tissues, when compared to paired normal tissues, and it was presumed that the over-stimulating muscarinic receptors via increasing acetylcholine is correlated to the gut carcinogenesis [39]. These above findings provide the rationale for serum CHE as a valuable biomarker for CRC diagnosis.
CEA, a classical biomarker of CRC, presented fair and similar diagnostic performances for overall CRC and early CRC (AUC = 0.758 and 0.742) in the present study. CEA has been recommended to be used in CRC relapse monitoring [40]. However, its low sensitivity limits its application in early diagnosis. In the present study, eight indicators (HGB, HCT, PALB, ALB, RBP, CHE, Ferritin and B2MG) had greater AUCs, when compared to CEA, for the diagnosis of early CRC. Furthermore, these had null or weak correlations with CEA, indicating that these indicators are superior or at least equal to CEA for the early diagnosis of CRC, in terms of diagnostic performance. In the eight indicators, beta-2-microglobulin (B2MG) is a biomarker for kidney filtration and cell turnover. This has been found to be elevated in some cancers, including CRC [41], and negatively correlated to the prognosis of recurrent CRC [42]. In a population-based cohort study followed-up for a maximum of 17 years, participants with the highest quartile of serum Β2MG concentration had a 121% higher risk of CRC incidence, when compared to those with the lowest quartile, and furthermore, this was much higher than the risk of total cancer incidence (25%) and independence of conventional clinical factors [43], indicating that B2MG is strongly associated with CRC incidence risk. The mechanism for the association of serum Β2MG concentrations with CRC carcinogenesis remains unclear. This is probably correlated to the pro-angiogenic, pro-tumorigenic, driving innate pro-inflammatory cytokines and growth promoting factors, epithelial-mesenchymal transition, and cell turnover [43]. For ferritin, which is a well-known iron binding protein, the reduction in serum ferritin level could be prior to anemia [20]. This is more remarkable in eastern countries, when compared to western countries, according to a meta-analysis [44].
Although the diagnostic value of conventional laboratory blood indicators for CRC was systematically and comprehensively analyzed in the present study, there were several limitations. First, we did not perform a multivariate analysis on these indicators due to the missing values in some indicators. Therefore, the independent indicators for CRC diagnosis need to be clarified in future studies. Second, since systematical blood tests could not be performed in outpatients and normal controls, merely inpatients with CRC, CRA and CRP were enrolled in the present study, which may cause the results to be inconsistent with the situation in the real world. Third, as a monocenter and retrospective study, further studies with a prospective and multicenter design and multivariate analysis are warranted to elucidate and validate the diagnostic significance of conventional laboratory blood tests in patients with CRC.
In summary, the investigators retrospectively and systematically analyzed the diagnostic performance of conventional laboratory blood indicators in differentiating CRC and CRA&P. It was found that most of the indicators have certain value for the diagnosis of CRC, including early CRC. Indicators correlated to anemia, nutrition status, and inflammation had greater value, when compared to the other indicators, and some of these were superior to that of CEA. Prospective studies with a more rigid design should be performed to validate these present results.